Matches in Nanopublications for { ?s ?p "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP703437.RAgn8acRaFPaFeMgvjKqNMCwe2MEo_tqVNV9QeYHiHDJ4130_assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP703437.RAgn8acRaFPaFeMgvjKqNMCwe2MEo_tqVNV9QeYHiHDJ4130_provenance.
- NP411943.RAzaN50YjEQKBFsOv5kvNQBwbFcXdMefh7bBlV_t1TOjQ130_assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP411943.RAzaN50YjEQKBFsOv5kvNQBwbFcXdMefh7bBlV_t1TOjQ130_provenance.
- assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1043030.RAcSZAr472UjI-UjWeE5mykJxGb1DG9_d82Z25Ijw6O0U130_provenance.
- NP519011.RAlxlo3ZNsJOWU6CyOJGil04DJKQZLSGinmdHOEPHkHTs130_assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519011.RAlxlo3ZNsJOWU6CyOJGil04DJKQZLSGinmdHOEPHkHTs130_provenance.
- NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_provenance.
- NP1043029.RAnQNRUaOtWBuJja0KmbujlxduMHOzyoFjFrOBnSR4428130_assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1043029.RAnQNRUaOtWBuJja0KmbujlxduMHOzyoFjFrOBnSR4428130_provenance.